Related references
Note: Only part of the references are listed.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Erin Larkins et al.
ONCOLOGIST (2017)
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Kirstine Jacobsen et al.
NATURE COMMUNICATIONS (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
Paul Geeleher et al.
GENOME BIOLOGY (2016)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2014)
Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
Abdul-Rahman Jazieh et al.
ANNALS OF THORACIC MEDICINE (2013)
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?
Aaron R. Hansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
Renato G. Martins et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang et al.
NUCLEIC ACIDS RESEARCH (2013)
Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
Ferdows Ather et al.
PLOS ONE (2013)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells
Yurie Tonoike et al.
BMC CELL BIOLOGY (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Kenichi Suda et al.
Journal of Thoracic Oncology (2010)
Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era
Myung-Ju Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases
Tomoya Kawaguchi et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Head and neck cancer: Changing epidemiology, diagnosis, and treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2008)
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma
Fabienne Thomas et al.
CLINICAL CANCER RESEARCH (2007)
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Fumiyuki Yamasaki et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Periplakin-dependent re-organisation of keratin cytoskeleton and loss of collective migration in keratin-8-downregulated epithelial sheets
Heather A. Long et al.
JOURNAL OF CELL SCIENCE (2006)
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR
EEW Cohen et al.
CLINICAL CANCER RESEARCH (2005)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Binding of protein kinase B to the plakin family member periplakin
APJ van den Heuvel et al.
JOURNAL OF CELL SCIENCE (2002)
Epithelial barrier function: assembly and structural features of the cornified cell envelope
AE Kalinin et al.
BIOESSAYS (2002)
dbSNP: the NCBI database of genetic variation
ST Sherry et al.
NUCLEIC ACIDS RESEARCH (2001)
Share Paper
